Literature DB >> 15452246

Rapid human immunodeficiency virus decay in highly active antiretroviral therapy (HAART)-experienced children after starting mega-HAART.

Nottasorn Plipat1, Ping K Ruan, Terence Fenton, Ram Yogev.   

Abstract

Increasing numbers of patients are treated with mega-highly active antiretroviral therapy (HAART), or multiple-combination antiretroviral therapy, in an attempt to overcome the viral resistance that has contributed to treatment failure. Studies of human immunodeficiency virus (HIV) viral dynamics are used to quantify the potency of a given regimen. While mega-HAART is expected to provide potent therapy, its potency among heavily experienced HIV-infected children who have failed previous treatment is untested. HIV dynamics studies performed in children have provided minimal information on viral dynamics during mega-HAART. The present study estimates first- and second-phase viral dynamics in six children on mega-HAART, following failure of combination therapy. The first phase of viral decay was rapid, relative to rates reported in previous pediatric studies (median delta = 0.778d(-1), range = 0.583 to 1.088, half-life 1 [t1(1/2)] = 0.894d), while the second phase revealed results similar to those of previous studies (median mu = 0.026d(-1), range = -0.005 to 0.206, t2(1/2) = 9.316d). This indicates that mega-HAART can provide potent therapy among heavily experienced pediatric patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452246      PMCID: PMC521824          DOI: 10.1128/JVI.78.20.11272-11275.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  12 in total

1.  Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials.

Authors:  H Wu; A A Ding
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

Review 2.  Viral dynamics in HIV-1 infection.

Authors:  D Finzi; R F Siliciano
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

3.  Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.

Authors:  A V Herz; S Bonhoeffer; R M Anderson; R M May; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

5.  Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.

Authors:  J S Montaner; P R Harrigan; N Jahnke; J Raboud; E Castillo; R S Hogg; B Yip; M Harris; V Montessori; M V O'Shaughnessy
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

6.  A comparison study of models and fitting procedures for biphasic viral dynamics in HIV-1 infected patients treated with antiviral therapies.

Authors:  A A Ding; H Wu
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

7.  Relationships between antiviral treatment effects and biphasic viral decay rates in modeling HIV dynamics.

Authors:  A A Ding; H Wu
Journal:  Math Biosci       Date:  1999-08       Impact factor: 2.144

8.  Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points.

Authors:  H Wu; D R Kuritzkes; D R McClernon; H Kessler; E Connick; A Landay; G Spear; M Heath-Chiozzi; F Rousseau; L Fox; J Spritzler; J M Leonard; M M Lederman
Journal:  J Infect Dis       Date:  1999-04       Impact factor: 5.226

9.  Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants.

Authors:  K Luzuriaga; H Wu; M McManus; P Britto; W Borkowsky; S Burchett; B Smith; L Mofenson; J L Sullivan
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 10.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.

Authors:  M S Hirsch; B Conway; R T D'Aquila; V A Johnson; F Brun-Vézinet; B Clotet; L M Demeter; S M Hammer; D M Jacobsen; D R Kuritzkes; C Loveday; J W Mellors; S Vella; D D Richman
Journal:  JAMA       Date:  1998-06-24       Impact factor: 56.272

View more
  4 in total

1.  Timing of the components of the HIV life cycle in productively infected CD4+ T cells in a population of HIV-infected individuals.

Authors:  John M Murray; Anthony D Kelleher; David A Cooper
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

2.  Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

Authors:  Kenneth E Sherman; Jeremie Guedj; Mohamed Tarek Shata; Jason T Blackard; Susan D Rouster; Mario Castro; Judith Feinberg; Richard K Sterling; Zachary Goodman; Bruce J Aronow; Alan S Perelson
Journal:  Sci Transl Med       Date:  2014-07-23       Impact factor: 17.956

3.  Simultaneous quantification of 9-(beta-D-1,3-dioxolan-4-yl)guanine, Amdoxovir and Zidovudine in human plasma by liquid chromatography-tandem mass spectrometric assay.

Authors:  Emilie Fromentin; Ghazia Asif; Aleksandr Obikhod; Selwyn J Hurwitz; Raymond F Schinazi
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-08-27       Impact factor: 3.205

4.  Optimal timing and duration of induction therapy for HIV-1 infection.

Authors:  Marcel E Curlin; Shyamala Iyer; John E Mittler
Journal:  PLoS Comput Biol       Date:  2007-07       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.